Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : O304
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Ivy Capital
Deal Size : Undisclosed
Deal Type : Funding
China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program
Details : The funding and connections within the Chinese Biotech and Pharmaceutical markets, will be important to support a speedy and global development of O304X in several major indications.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 20, 2020
Lead Product(s) : O304
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Ivy Capital
Deal Size : Undisclosed
Deal Type : Funding